% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vanderWeijst:181959,
      author       = {L. van der Weijst and D. Azria and P. Berkovic and P.
                      Boisselier and E. Briers and R. Bultijnck and J.
                      Chang-Claude$^*$ and A. Choudhury and G. Defraene and S.
                      Demontois and R. M. Elliott and D. Ennis and C. Faivre-Finn
                      and M. Franceschini and T. Giandini and A. Giraldo and S.
                      Gutiérrez-Enríquez and C. Herskind and D. S. Higginson and
                      S. L. Kerns and K. Johnson and M. Lambrecht and P. Lang and
                      M. Ramos and T. Rancati and A. Rimner and B. S. Rosenstein
                      and D. De Ruysscher and A. Salem and C. Sangalli and P.
                      Seibold$^*$ and P. Sosa Fajardo and E. Sperk and H. Stobart
                      and H. Summersgill and V. Surmont and P. Symonds and B.
                      Taboada-Valladares and C. J. Talbot and A. Vega and L.
                      Veldeman and M. R. Veldwijk and T. Ward and A. Webb and C.
                      M. L. West and Y. Lievens},
      collaboration = {R. consortium},
      title        = {{T}he correlation between pre-treatment symptoms, acute and
                      late toxicity and patient-reported health-related quality of
                      life in non-small cell lung cancer patients: {R}esults of
                      the {REQUITE} study.},
      journal      = {Radiotherapy and oncology},
      volume       = {176},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2022-02329},
      pages        = {127-137},
      year         = {2022},
      note         = {2022 Oct 3;176:127-137},
      abstract     = {To investigate the association between clinician-scored
                      toxicities and patient-reported health-related quality of
                      life (HRQoL), in early-stage (ES-) and locally-advanced
                      (LA-) non-small cell lung cancer (NSCLC) patients receiving
                      loco-regional radiotherapy, included in the international
                      real-world REQUITE study.Clinicians scored eleven
                      radiotherapy-related toxicities (and baseline symptoms) with
                      the Common Terminology Criteria for Adverse Events version
                      4. HRQoL was assessed with the European Organization for
                      Research and Treatment of Cancer core HRQoL questionnaire
                      (EORTC-QLQ-C30). Statistical analyses used the mixed-model
                      method; statistical significance was set at p=0.01. Analyses
                      were performed for baseline and subsequent time points up to
                      2 years after radiotherapy and per treatment modality,
                      radiotherapy technique and disease stage.Data of 435
                      patients were analysed. Pre-treatment, overall symptoms,
                      dyspnea, chest wall pain, dysphagia and cough impacted
                      overall HRQoL and specific domains. At subsequent time
                      points, cough and dysphagia were overtaken by pericarditis
                      in affecting HRQoL. Toxicities during concurrent
                      chemo-radiotherapy and 3-dimensional radiotherapy had the
                      most impact on HRQoL. Conversely, toxicities in sequential
                      chemo-radiotherapy and SBRT had limited impact on patients'
                      HRQoL. Stage impacts the correlations: LA-NSCLC patients are
                      more adversely affected by toxicity than ES-NSCLC patients,
                      mimicking the results of radiotherapy technique and
                      treatment modality.Pre-treatment symptoms and acute/late
                      toxicities variously impact HRQoL of ES- and LA-NSCLC
                      patients undergoing different treatment approaches and
                      radiotherapy techniques. Throughout the disease, dyspnea
                      seems crucial in this association, highlighting the
                      additional effect of co-existing comorbidities. Our data
                      call for optimized radiotherapy limiting toxicities that may
                      affect patients' HRQoL.},
      keywords     = {Health-related quality of life (Other) / association
                      (Other) / non-small cell lung cancer (Other) /
                      patient-reported outcomes (Other) / radiotherapy (Other) /
                      technique (Other) / toxicity (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36195214},
      doi          = {10.1016/j.radonc.2022.09.020},
      url          = {https://inrepo02.dkfz.de/record/181959},
}